Fritextsökning
Innehållstyper
-
After the threat of tariffs – Novartis invests 230 billion in the USA
Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...
-
Cantargia utser Hilde Steineger till ny vd
Det Lundbaserade forskningsbolaget Cantargia har utsett Hilde Steineger till ny vd.
-
Rise and Scantox cease conducting animal testing in Stockholm
Access to in vivo toxicology services is significantly decreasing in the Stockholm area as Rise shuts down animal testing and Scantox reorganizes. ”The costs ar...
-
GSK i stort Kinasamarbete – ska utveckla ett dussin nya läkemedel
Den brittiska läkemedelsjätten GSK har tecknat ett stort samarbetsavtal med kinesiska Hengrui Pharma om utveckling av upp till 12 nya läkemedel.
-
New moves around Nykode's management – withdrawal of resignations
Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.
-
CT technology for when the inside matters
ZEISS METROTOM 1 now at #HandsOnMetrology.
-
Discover Precision: Join ZEISS at the Control Fair in Stuttgart
May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.
-
Reveal the Structures and Functions of Life
Super-resolution microscopes from ZEISS.
-
ZEISS supports the transition of spatial biology to clinical research
Slide scanner ZEISS Axioscan 7 spatial biology provides scalable workflow automation.
-
Tau-targeted Alzheimer's drug gets Fast Track designation in the USA
Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
-
Meet us at Control 2025
Innovations that drive efficiency.
-
Computed tomography in measurement of medical plastic products
Watch the recordings from ZEISS Quality Innovation Summit.
-
FDA plans to replace animal testing with AI – “Paradigm shift”
The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met...
-
FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy
FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...
-
ZEISS continues to drive digital era forward in ophthalmology
2 million digitally planned cataract cases in the U.S. alone.
-
Eli Lilly requests re-examination of Alzheimer's drug recommendation
Eli Lilly has requested that the EMA re-examine its opinion on the company's Alzheimer's drug, Kisunla, the agency announced on Friday.
-
ZEN core now available for all ZEISS scanning electron microscopes
Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.
-
Kennedy stoppar 22 projekt inom mRNA-vaccin – experter varnar för följderna
USA:s hälsodepartement avbryter finansieringen av 22 projekt som utvecklar mRNA-baserade vacciner, och växlar över till vad som hävdas vara ”säkrare och bredare...
-
The top five most expensive drugs in 2025
New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...
-
Success for Genmab's antibody-drug conjugate
The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
-
Improving Nano-Structured Surfaces for Implants with Scanning Electron Microscopy
Promimic, a Swedish company specializing in the development and marketing of nano-structured surfaces for implants, heavily relies on scanning electron microscopes.
-
Eli Lilly värvar toppforskaren Kaj Blennow – ska leda Alzheimerprojekt
Eli Lilly rekryterar Kaj Blennow, en av Sveriges och världens främsta forskare inom Alzheimers sjukdom, till en post som Vice President of Neuroscience Biomarker Development.
-
An organ seldom in the spotlight – but utterly vital
The kidneys consist of more than 40 types of cells and have more functions in the body than most people know. Julie Williams leads AstraZeneca’s work in preclin...
-
Vaccine skeptic David Geier to lead study on link to autism
The American government is to launch a study on whether vaccines cause autism – and has appointed a well-known vaccine skeptic to lead the analysis.
BREAKING